ACADIA Pharmaceuticals Added to Russell 2000 Index
The annual reconstitution of the Russell 3000 captures the 3,000 largest
U.S. stocks as of the end of May, ranking them by total market
capitalization. The largest 1,000 companies in this ranking make up the
Russell 1000 and the next 2,000 companies comprise the Russell 2000. The
Russell 3000 also serves as the U.S. component to the Russell Global
Index. Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for passive
and active investment strategies. Approximately
About Russell Investments
Russell Investments (Russell) is a global asset manager and one of only a few firms that offers actively managed multi-asset portfolios and services that include advice, investments and implementation. Russell stands with institutional investors, financial advisors and individuals working with their advisors—using the firm’s core capabilities that extend across capital market insights, manager research, portfolio construction, portfolio implementation and indexes to help each achieve their desired investment outcomes.
About
ACADIA is a biopharmaceutical company focused on innovative treatments
that address unmet medical needs in neurological and related central
nervous system disorders. ACADIA has a pipeline of product candidates
led by pimavanserin, which is in Phase III development as a potential
first-in-class treatment for Parkinson's disease psychosis. ACADIA also
has clinical-stage programs for chronic pain and glaucoma in
collaboration with
Forward-Looking Statements
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to the progress and timing of ACADIA’s
drug discovery and development programs, either alone or with a partner,
including clinical trials, and the benefits to be derived from ACADIA’s
product candidates, in each case including pimavanserin. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties. Actual
events or results may differ materially from those projected in any of
such statements due to various factors, including the risks and
uncertainties inherent in drug discovery, development and
commercialization, and collaborations with others, and the fact that
past results of clinical trials may not be indicative of future trial
results. For a discussion of these and other factors, please refer to
ACADIA’s annual report on Form 10-K for the year ended December 31, 2012
as well as ACADIA’s subsequent filings with the
Source:
ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, Executive
Vice President,
Chief Financial Officer and Chief Business
Officer
Lisa Barthelemy, Director of Investor Relations
(858)
558-2871